查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1412402

多形性膠質母細胞瘤治療藥物市場：按類型、最終用戶分類 - 全球預測 2024-2030

Glioblastoma Multiforme Treatment Market by Type (Chemotherapy, Combined Modality Therapy, Medications), End-Users (Hospitals, Speciality Centers) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年多形性膠質母細胞瘤治療市場規模為31.1億美元，2024年達33.6億美元，2030年達53.9億美元，複合年成長率為8.17%。

多形性膠質母細胞瘤治療的全球市場

主要市場統計
基準年[2023] 31.1億美元
預測年份 [2024] 33.6億美元
預測年份 [2030] 53.9億美元
複合年成長率（%） 8.17%
多形性膠質母細胞瘤治療藥物市場-IMG1

FPNV定位矩陣

FPNV定位矩陣對於評估多形性膠質母細胞瘤藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對多形性膠質母細胞瘤治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2-市場開拓：我們深入研究利潤豐厚的新興市場並分析其在成熟細分市場的滲透率。

3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1-多形性膠質母細胞瘤治療市場的市場規模與預測是多少？

2-在多形性膠質母細胞瘤治療藥物市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3-多形性膠質母細胞瘤治療市場的技術趨勢和法律規範是什麼？

4-多形性膠質母細胞瘤治療藥物市場主要供應商的市場佔有率為何？

5-進入多形性膠質母細胞瘤藥物市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 腦部和神經系統疾病盛行率上升
      • 提高對腦​​部疾病和腫瘤的早期發現和治療的認知
      • 改善整個經濟領域的醫療基礎設施
    • 抑制因素
      • 治療多形性神經膠母細胞瘤的高費用和併發症
    • 機會
      • 加大投入加速臨床研究
      • 治療多形性神經膠母細胞瘤新技術的出現
    • 任務
      • 與多形性膠質母細胞瘤藥物相關的報銷問題和嚴格的監管合規性
  • 市場區隔分析
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範

第6章多形性膠質母細胞瘤治療藥物市場：依類型

  • 化療
  • 綜合療法
  • 藥品
  • 放射治療
  • 外科手術
  • 標靶治療

第7章多形性膠質母細胞瘤治療藥物市場：依最終使用者分類

  • 醫院
  • 專業中心

第8章美洲多形性膠質母細胞瘤治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太多形性膠質母細胞瘤治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲多形性膠質母細胞瘤治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭形勢

  • FPNV定位矩陣
  • 市場佔有率分析：主要企業
  • 主要企業競爭情境分析

第12章競爭產品組合

  • 主要公司簡介
    • AIVITA Biomedical, Inc.
    • Angiochem Inc.
    • Avant Immunotherapeutics, Inc.
    • Bayer AG
    • Chimerix Inc.
    • Daiichi Sankyo Company, Limited
    • Diffusion Pharmaceuticals Inc.
    • DNAtrix, Inc.
    • Eisai Co., Ltd.
    • F. Hoffmann-La Roche Ltd
    • Karyopharm Therapeutics Inc.
    • Kazia Therapeutics Limited
    • Lineage Cell Therapeutics, Inc.
    • Merck & Co. Inc.
    • Moleculin Biotech, Inc.
    • Novocure GmbH
    • OncoSynergy, Inc.
    • Pfizer Inc.
    • Sapience Therapeutics, Inc.
    • SonALAsense
    • Sumitomo Dainippon Pharma Oncology, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • VBI Vaccines Inc.
    • VBL Therapeutics
  • 主要產品系列

第13章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-C002B1C99723

[187 Pages Report] The Glioblastoma Multiforme Treatment Market size was estimated at USD 3.11 billion in 2023 and expected to reach USD 3.36 billion in 2024, at a CAGR 8.17% to reach USD 5.39 billion by 2030.

Global Glioblastoma Multiforme Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 3.11 billion
Estimated Year [2024] USD 3.36 billion
Forecast Year [2030] USD 5.39 billion
CAGR (%) 8.17%
Glioblastoma Multiforme Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Glioblastoma Multiforme Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Glioblastoma Multiforme Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Glioblastoma Multiforme Treatment Market, highlighting leading vendors and their innovative profiles. These include AIVITA Biomedical, Inc., Angiochem Inc., Avant Immunotherapeutics, Inc., Bayer AG, Chimerix Inc., Daiichi Sankyo Company, Limited, Diffusion Pharmaceuticals Inc., DNAtrix, Inc., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd, Karyopharm Therapeutics Inc., Kazia Therapeutics Limited, Lineage Cell Therapeutics, Inc., Merck & Co. Inc., Moleculin Biotech, Inc., Novocure GmbH, OncoSynergy, Inc., Pfizer Inc., Sapience Therapeutics, Inc., SonALAsense, Sumitomo Dainippon Pharma Oncology, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., VBI Vaccines Inc., and VBL Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Glioblastoma Multiforme Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Chemotherapy
    • Combined Modality Therapy
    • Medications
    • Radiation Therapy
    • Surgery
    • Targeted Therapy
  • End-Users
    • Hospitals
    • Speciality Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Glioblastoma Multiforme Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Glioblastoma Multiforme Treatment Market?

3. What are the technology trends and regulatory frameworks in the Glioblastoma Multiforme Treatment Market?

4. What is the market share of the leading vendors in the Glioblastoma Multiforme Treatment Market?

5. Which modes and strategic moves are suitable for entering the Glioblastoma Multiforme Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Glioblastoma Multiforme Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of brain and neurological diseases
      • 5.1.1.2. Growing awareness of early detection and treatments related to brain disorders and tumors
      • 5.1.1.3. Improved healthcare infrastructure across economies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and complications associated with glioblastoma multiforme treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investments to foster clinical research
      • 5.1.3.2. Emerging new techniques to treat glioblastoma multiforme
    • 5.1.4. Challenges
      • 5.1.4.1. Reimbursement issues and stringent regulatory compliances associated with glioblastoma multiforme treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Glioblastoma Multiforme Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Combined Modality Therapy
  • 6.4. Medications
  • 6.5. Radiation Therapy
  • 6.6. Surgery
  • 6.7. Targeted Therapy

7. Glioblastoma Multiforme Treatment Market, by End-Users

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Speciality Centers

8. Americas Glioblastoma Multiforme Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Glioblastoma Multiforme Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Glioblastoma Multiforme Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. AIVITA Biomedical, Inc.
    • 12.1.2. Angiochem Inc.
    • 12.1.3. Avant Immunotherapeutics, Inc.
    • 12.1.4. Bayer AG
    • 12.1.5. Chimerix Inc.
    • 12.1.6. Daiichi Sankyo Company, Limited
    • 12.1.7. Diffusion Pharmaceuticals Inc.
    • 12.1.8. DNAtrix, Inc.
    • 12.1.9. Eisai Co., Ltd.
    • 12.1.10. F. Hoffmann-La Roche Ltd
    • 12.1.11. Karyopharm Therapeutics Inc.
    • 12.1.12. Kazia Therapeutics Limited
    • 12.1.13. Lineage Cell Therapeutics, Inc.
    • 12.1.14. Merck & Co. Inc.
    • 12.1.15. Moleculin Biotech, Inc.
    • 12.1.16. Novocure GmbH
    • 12.1.17. OncoSynergy, Inc.
    • 12.1.18. Pfizer Inc.
    • 12.1.19. Sapience Therapeutics, Inc.
    • 12.1.20. SonALAsense
    • 12.1.21. Sumitomo Dainippon Pharma Oncology, Inc.
    • 12.1.22. Sun Pharmaceutical Industries Ltd.
    • 12.1.23. Teva Pharmaceutical Industries Ltd.
    • 12.1.24. VBI Vaccines Inc.
    • 12.1.25. VBL Therapeutics
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLIOBLASTOMA MULTIFORME TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 10. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COMBINED MODALITY THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 13. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. GLIOBLASTOMA MULTIFORME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 102. GLIOBLASTOMA MULTIFORME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. GLIOBLASTOMA MULTIFORME TREATMENT MARKET LICENSE & PRICING